Patents by Inventor Kiminari Ito

Kiminari Ito has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8168429
    Abstract: The present invention provides useful means in an expansion culture system for a hematopoietic cell (hematopoietic stem cell, hematopoietic progenitor cell). Specifically, the present invention provides a composition for expanding a hematopoietic cell (hematopoietic stem cell, hematopoietic progenitor cell) containing recombinant human serum albumin; a serum-free medium for expanding a hematopoietic cell containing a basal medium and recombinant human serum albumin; a method of expanding a hematopoietic cell comprising culturing a hematopoietic cell in a serum-free medium containing recombinant human serum albumin, and a culture of a hematopoietic cell that can be obtained by the expansion method.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: May 1, 2012
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Asako Hatsuyama, Kiminari Ito, Tatsutoshi Nakahata
  • Publication number: 20070166825
    Abstract: The present invention provides useful means in an expansion culture system for a hematopoietic cell (hematopoietic stem cell, hematopoietic progenitor cell). Specifically, the present invention provides a composition for expanding a hematopoietic cell (hematopoietic stem cell, hematopoietic progenitor cell) containing recombinant human serum albumin; a serum-free medium for expanding a hematopoietic cell containing a basal medium and recombinant human serum albumin; a method of expanding a hematopoietic cell comprising culturing a hematopoietic cell in a serum-free medium containing recombinant human serum albumin, and a culture of a hematopoietic cell that can be obtained by the expansion method.
    Type: Application
    Filed: July 21, 2004
    Publication date: July 19, 2007
    Applicant: Mitsubishi Pharma Corporation
    Inventors: Asako Hatsuyama, Kiminari Ito, Tatsutoshi Nakahata
  • Patent number: 6692958
    Abstract: Activated lymphocytes derived from cord blood are excellently effective for preventing and treating various types of tumors and various types of infection. With interleukin 2 and/or anti-CD3 antibody, the lymphocytes derived from the cord blood is prepared by segregating lymphocytes from the cord blood and proliferating the segregated lymphocytes directly in vitro or segregating monocytes from cord blood and proliferating the monocytes in vitro. Also, the cord blood-derived activated lymphocytes can be effectively used for preventing recurrence of the diseases and promoting the take of stem cells or other organs.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: February 17, 2004
    Assignee: Humantec Ltd.
    Inventors: Teruaki Sekine, Kiminari Ito, Norio Shimizu, Kenzo Bamba, Tomohiro Yamaguchi, Yasuyuki Kuroiwa
  • Patent number: 6544514
    Abstract: Compositions or medicaments comprising allogenic activated-CD4+ cells as the main ingredient, which are attributable to an organ or bone marrow transplantation donor, have an extremely beneficial effect for preventing recidivation of a tumor and remedying various infections such as viral infections, and autoimmune diseases such as phagocytosis, without causing any serious GVHD. The allogenic activated-CD4+ cells can be produced by separating lymphocyte cells or CD4+ cells from peripheral blood of the donor or removing CD8+ cells from the peripheral blood of the donor by using anti-CD8+ antibodies to obtain CD4+ cells and proliferating the CD4+ cells thus prepared in proliferation activator.
    Type: Grant
    Filed: April 8, 1999
    Date of Patent: April 8, 2003
    Inventors: Teruaki Sekine, Kiminari Ito, Kenzo Bamba, Yasuyuki Kuroiwa
  • Publication number: 20020086063
    Abstract: Activated lymphocytes derived from cord blood are excellently effective for preventing and treating various types of tumors and various types of infection. With interleukin 2 and/or anti-CD3 antibody, the lymphocytes derived from the cord blood is prepared by segregating lymphocytes from the cord blood and proliferating the segregated lymphocytes directly in vitro or segregating monocytes from cord blood and proliferating the monocytes in vitro. Also, the cord blood-derived activated lymphocytes can be effectively used for preventing recurrence of the diseases and promoting the take of stem cells or other organs.
    Type: Application
    Filed: December 4, 2001
    Publication date: July 4, 2002
    Inventors: Teruaki Sekine, Kiminari Ito, Norio Shimizu, Kenzo Bamba, Tomohiro Yamaguchi, Yasuyuki Kuroiwa
  • Publication number: 20020001576
    Abstract: Medicaments or preparations containing allogenic activated-CD4+ cells as the main ingradient, which are attributable to an organ or bone marrow transplantation donor, have an extremely beneficial effect for preventing recidivation of a tumor and remedying various infections such as viral infections, and autoimmune diseases such as phagocytosis, without causing any serious GVHD. The allogenic activated-CD4+ cells can be produced by separating lymphocyte cells or CD4+ cells from peripheral blood of the donor or removing CD8+ cells from the peripheral blood of the donor by using anti-CD8+ antibodies to obtain CD4+ cells and proliferating the CD4+ cells thus prepared in a proliferation activator.
    Type: Application
    Filed: April 8, 1999
    Publication date: January 3, 2002
    Inventors: TERUAKI SEKINE, KIMINARI ITO, KENZO BAMBA, YASUYUKI KUROIWA